arrow
S

Stefani Spranger

MIT
H指数:48
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

使用Trikine免疫治疗剂重塑细胞表面的STAT信号通路

Science
IF45.8
2026-02-190
PRE
Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer

突变型p53利用增强子来提高免疫抑制性趋化因子表达并削弱免疫检查点抑制剂在胰腺癌中的作用

Immunity
IF26.3
2025-06-300
OA
Transforming ovarian cancer care by targeting minimal residual disease

通过针对最小残留疾病转变卵巢癌护理

MED
IF11.8
2023-11-011
OAAI
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti- CTLA-4 antibodies

肿瘤内调节性T细胞耗竭和CTLA-4拮抗作用都是抗CTLA-4抗体的最大功效所必需的

2023-07-2411
OAAI
A prime editor mouse to model a broad spectrum of somatic mutations in vivo

prime editor小鼠在体内建立广泛的体细胞突变模型

2023-05-1120
OA
Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation

瓶刷前药释放TLR7/8激动剂的工程动力学使肿瘤集中免疫刺激成为可能

2023-04-2120
OAAI
Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer

组织特异性丰富的干扰素-γ 驱动调节性T细胞抑制细胞毒性T细胞对肺癌的DC1-mediated引发

IMMUNITY
IF26.3
2023-02-0149
OA